7 / 82
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 29, No 1, January/February 2018
AFRICA
5
contribution of Gershlick
et al
.,
1
which may be recommended for
the formulation of solutions to enable prevention or reduction in
STEMI-related mortality and morbidity in South Africa.
References
1.
Gershlick AH, Banning AP, Myat A, Verheugt FW, Gersh BJ.
ST-segment elevation myocardial infarction 1: reperfusion therapy for
STEMI: is there still a role for thrombolysis in the era of primary percu-
taneous coronary intervention?
Lancet
2013;
382
(9892): 624–632. DOI:
10.1016/S0140-6736(13)61454-3.
2.
Ibanez B, James S, Agewall S,
et al
. 2017 ESC guidelines for the
management of acute myocardial infarction in patients presenting
with ST-segment elevation: the task force for the management of acute
myocardial infarction in patients presenting with ST-segment elevation
of the European Society of Cardiology (ESC).
Eur Heart J
2018;
39
:
119–177.
https://doi.org/10.1093/eurheartj/ehx393.3.
Mortality and causes of death in South Africa, 2015: Findings from
death notification. Statistics South Africa. Statistical release P0309.3.
http://www.statssa.gov.za/publications/P03093/P030932015.pdf4.
Mid-year population estimates 2015. Statistics South Africa. Statistical
release P0302.
https://www.statssa.gov.za/publications/P0302/P03022015.pdf
5.
Use of health facilities and levels of selected health conditions in South
Africa: Findings from the General Household Survey, 2011. Statistics
South Africa. Report no. 03-00-05 (2011).
http://www.statssa.gov.za/publications/Report-03-00-05/Report-03-00-052011.pdf
6.
Stassen W, Wallis LA, Lambert C, Castren M, Kurland L. Percutaenous
coronary intervention still not accessible for many South Africans.
Afr J Emerg Med
2017;
7
: 105–107.
http://dx.doi.org/10.1016/j.afjem.2017.04.009.
7.
Baliga RR, Bahl VK, Alexander T, Mullasari A, Manga P, Dec GW,
Narula J. Management of STEMI in low- and middle-income countries.
Glob Heart
2014;
9
(4): 469–510. doi: 10.1016/j.gheart.2014.11.001.
Confidence Through Clinical and Real World Experience
1-3
Millions of Patients Treated Worldwide Across Multiple Indications
4
#1 Scripted Non-VKA Oral Anticoagulant by Cardiologists*
*Impact RX Data 2016
NOAC: Non Vitamin K Oral Anticoagulant
REFERENCES:
1. Patel M.R., Mahaffey K.W., Garg J.
et al
. Rivaroxaban versus warfarin in non-valvular atrial fi brillation.
N Engl J Med
. 2011;365(10):883–91. 2. Tamayo S., Peacock W.F., Patel M.R.,
et al
. Characterizing
major bleeding in patients with nonvalvular atrial fi brillation: A pharmacovigilance study of 27 467 patients taking rivaroxaban.
Clin Cardiol
. 2015;38(2):63–8. 3. Camm A.J., Amarenco P., Haas S.
et al
. XANTUS: A
Real-World, Prospective, Observational Study. 4. Calculation based on IMS Health MIDAS, Database: Monthly Sales January 2017.
S4 Xarelto 15: Each film-coated tablet contains rivaroxaban 15 mg. Reg. No: 46/8.2/0111; Namibia NS2 : 12/8.2/0006; S2 Botswana: BOT1302296; Zimbabwe: PP10 Reg. 2017/10.2/5363
S4 Xarelto 20: Each film-coated tablet contains rivaroxaban 20 mg. Reg. No: 46/8.2/0112;Namibia NS2 : 12/8.2/0007; S2 Botswana: BOT1302297; Zimbabwe: PP10 Reg. 2017/10.2/5364
PHARMACOLOGICAL CLASSIFICATION:
A.8.2 Anticoagulants.
INDICATIONS:
(1) Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (SPAF); (2) Treatment of deep vein thrombosis
(DVT) and for the prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE); (3) Treatment of pulmonary embolism (PE) and for the prevention of recurrent pulmonary embolism (PE) and deep
vein thrombosis (DVT). For full prescribing information, refer to the package insert approved by the Medicines Regulatory Authority (MCC).
HCR:
Bayer (Pty) Ltd, Co. Reg. No.: 1968/011192/07, 27 Wrench Road, Isando,
1609. Tel: 011 921 5044 Fax: 011 921 5041.
L.ZA.MKT.GM06.2017.1808
© Bayer June 2017